These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23239659)

  • 1. [Multi-mode MRI-based intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) reduces hemorrhagic transformation in ischemic stroke patients].
    Lin YH; Lou M; Zhu RY; Yan YQ; Zhen ZC; Ding MP
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 41(6):665-71. PubMed ID: 23239659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume.
    Selim M; Fink JN; Kumar S; Caplan LR; Horkan C; Chen Y; Linfante I; Schlaug G
    Stroke; 2002 Aug; 33(8):2047-52. PubMed ID: 12154261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
    Larrue V; von Kummer R R; Müller A; Bluhmki E
    Stroke; 2001 Feb; 32(2):438-41. PubMed ID: 11157179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
    Nisar T; Hanumanthu R; Khandelwal P
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
    Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
    Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of MRI-based selection for recombinant tissue plasminogen activator treatment: responder analysis of outcome in the 3-hour time window.
    Sølling C; Hjort N; Ashkanian M; Østergaard L; Andersen G
    Cerebrovasc Dis; 2009; 27(3):223-9. PubMed ID: 19176954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
    Tanne D; Kasner SE; Demchuk AM; Koren-Morag N; Hanson S; Grond M; Levine SR
    Circulation; 2002 Apr; 105(14):1679-85. PubMed ID: 11940547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and effectiveness of low-dose recombinant tissue plasminogen activator (0.6 mg/kg) therapy for elderly acute ischemic stroke patients (≥ 80 years old) in the pre-endovascular era.
    Takayanagi S; Ochi T; Hanakita S; Suzuki Y; Maeda K
    Neurol Med Chir (Tokyo); 2014 Jun; 54(6):435-40. PubMed ID: 24670312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator.
    Nighoghossian N; Hermier M; Adeleine P; Derex L; Dugor JF; Philippeau F; Ylmaz H; Honnorat J; Dardel P; Berthezène Y; Froment JC; Trouillas P
    Stroke; 2003 Feb; 34(2):458-63. PubMed ID: 12574560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Hemorrhage Volume after Intravenous Thrombolysis.
    Shon SH; Heo SH; Kim BJ; Choi HY; Kwon Y; Yi SH; Lee JS; Kim YS; Kim HY; Koh SH; Chang DI
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2543-8. PubMed ID: 27444521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
    Thomalla G; Sobesky J; Köhrmann M; Fiebach JB; Fiehler J; Zaro Weber O; Kruetzelmann A; Kucinski T; Rosenkranz M; Röther J; Schellinger PD
    Stroke; 2007 Feb; 38(2):313-8. PubMed ID: 17204683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
    García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF
    Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke.
    Nagaraja N; Tasneem N; Shaban A; Dandapat S; Ahmed U; Policeni B; Olalde H; Shim H; Samaniego EA; Pieper C; Ortega-Gutierrez S; Leira EC; Adams HP
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1403-1411. PubMed ID: 29398533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute blood eosinophil count could be a potential biomarker for predicting haemorrhagic transformation after intravenous thrombolysis for acute ischaemic stroke.
    Jucevičiūtė N; Mikužis P; Balnytė R
    BMC Neurol; 2019 Jun; 19(1):127. PubMed ID: 31195995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety of intravenous thrombolysis in cerebral microbleeds patients with prior antiplatelet therapy].
    Yan SQ; Mao YY; Zhong GL; Zhang S; Lou M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 44(6):618-24. PubMed ID: 26822043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.